AZTR earnings analysis
What we found in AZTR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Azitra remains a pre-commercial, single-segment biotechnology company with no reported product revenue and a widening quarterly net loss of $3.35 million, although diluted EPS improved to negative $0.17 from negative $1.18 in the prior-year quarter. Cash rose to $6.7 million after $10.6 million of financing inflows, but six-month operating cash burn was $5.8 million and management said existing cash will not fund the next 12 months, creating substantial going-concern uncertainty. The pipeline retains planned 2026 milestones, but ATR-12 enrollment was paused for capital preservation, while dilution, NYSE compliance, and the continuing material weakness remain significant concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Loss Narrowed Sharply
- Second-quarter net loss was $3,347,660, or $0.17 per diluted share, versus a $2,888,993 loss, or $1.18 per diluted share, in the prior-year quarter. The per-share loss improved by $1.01 despite the net loss increasing by $458,667.
- Higher Corporate Costs Offset R&D Decline
- Quarterly operating expenses increased 19% to $3,419,168 from $2,871,352 in the prior-year period, driven by general and administrative expense rising 41% to $2,067,639. Research and development expense declined 4% to $1,351,529.
- Capital Raise Rebuilt Cash Balance
- Six-month financing activities provided $10,582,845, primarily from $10,377,703 of net private-placement proceeds, $215,950 from the ELOC and $196,800 from warrant exercises. Cash and equivalents increased to $6,727,810 from $2,068,083 at December 31, 2025.
- Equity Above NYSE Thresholds
- Stockholders’ equity increased to $7,334,339 at June 30, 2026 from $3,801,230 at December 31, 2025, exceeding the applicable NYSE American equity thresholds of $4.0 million and $6.0 million.
- Pipeline Milestones Remain Active
- Management plans a cosmetic study of ATR-COSF in the second half of 2026 and expects to announce initial ATR-04 Cohort 1 trial data around Q4 2026. ATR-12 enrollment was paused in June 2026 for capital preservation.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-Concern Funding Requirement
- The filing continues to identify substantial doubt about going-concern status: the company had an accumulated deficit of approximately $75.8 million, used approximately $5.8 million in operating cash during the first six months, and stated that its $6.7 million of cash will not cover the proposed plan of operations for the next 12 months.
- Extreme Warrant Overhang and Dilution
- As of June 30, 2026, 60,603,742 common shares were outstanding compared with warrants for 219,470,313 shares and options for 651,871 shares. The filing specifically notes that exercise, ELOC sales and other equity issuances could substantially dilute existing holders.
- NYSE American Delisting Exposure
- The company remains subject to NYSE American compliance proceedings through April 1, 2027, despite reporting approximately $7.3 million of equity versus the $4.0 million and $6.0 million applicable thresholds. Continued net losses could again reduce equity below those requirements and lead to delisting proceedings.
- Material Weakness Persists
- A material weakness in disclosure controls remains in place because of inadequate segregation of accounting functions; management concluded that disclosure controls were not effective as of June 30, 2026.
- Trade Policy and Supply-Cost Risk
- The company added exposure to changing U.S. and international trade policies because it relies on foreign manufacturers and service providers. The filing cites a 10% U.S. tariff on imports from many countries and warns that future tariffs could increase manufacturing and clinical-support costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.17
- Segment
- Single reportable operating segment; three-month operating expenses were $3,419,168, including $2,067,639 of general and administrative expense and $1,351,529 of research and development expense.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that ATR-COSF cosmetic testing is planned for the second half of 2026, ATR-04 initial Cohort 1 data is planned around Q4 2026, and research and development expenses are expected to significantly increase due to planned clinical activity.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Azitra's Q1 2026 10-Q filing shows a significant net loss of approximately $3.93 million, widening from a loss of $3.07 million in Q1 2025. The company has reported no revenue, while cash balances improved to $10.1…
- 10-K · February 27, 2026
- Azitra positions itself as an early‑stage precision dermatology company with a proprietary microbial library and platform for engineering topical live biotherapeutics and recombinant proteins. The company advanced…
- 10-Q · May 9, 2024
- Azitra reported zero revenue for the quarter (compared with $113,300 in Q1 2023) and a net loss of $2,932,875 (net loss per share $(0.15)). Cash increased to $3,001,158 at March 31, 2024 (from $1,795,989 at December 31,…
- 10-Q · November 14, 2023
- Azitra reported Q3 revenue of $310,700 (up from $48,500 in Q3 2022 and $172,000 in Q2 2023) with net loss per share improving to $(0.16) for the quarter. Operating loss remains significant (loss from operations…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AZTR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever